Lake Street Capital Markets has kicked off coverage of OncoCyte (OCX, Financial) with a buy rating, highlighting significant growth potential in the transplant rejection testing market. The firm has set a price target of $5, suggesting a 55% upside from the closing price on March 27. OncoCyte aims to transform the organ rejection testing landscape with its VitaGraft Plus test, which uses donor-derived cell-free DNA (dd-cfDNA). Although not yet FDA-approved, an application is anticipated soon with potential approval by 2026. Kidney transplant volumes have notably increased, averaging a 5% growth annually over the past decade.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for OncoCyte Corp (OCX, Financial) is $4.13 with a high estimate of $4.25 and a low estimate of $4.00. The average target implies an upside of 32.21% from the current price of $3.12. More detailed estimate data can be found on the OncoCyte Corp (OCX) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, OncoCyte Corp's (OCX, Financial) average brokerage recommendation is currently 2.7, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for OncoCyte Corp (OCX, Financial) in one year is $2.65, suggesting a downside of 15.06% from the current price of $3.12. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the OncoCyte Corp (OCX) Summary page.
